scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.NMD.2018.01.003 |
P698 | PubMed publication ID | 29433793 |
P50 | author | Ivon Cuscó | Q34448131 |
Sara Bernal | Q73617080 | ||
P2093 | author name string | Pablo Fuentes-Prior | |
Salud Borrego | |||
Concepción Hernández-Chico | |||
José M Millán | |||
Raquel M Fernández | |||
Francesca March | |||
Adoración Venceslá | |||
Eduardo F Tizzano | |||
Laura Alías | |||
Elena Aller | |||
Maite Calucho | |||
Francisco J Rodríguez-Álvarez | |||
P433 | issue | 3 | |
P304 | page(s) | 208-215 | |
P577 | publication date | 2018-01-11 | |
P1433 | published in | Neuromuscular Disorders | Q1981326 |
P1476 | title | Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases | |
P478 | volume | 28 |
Q55339830 | Accurate diagnosis of spinal muscular atrophy and 22q11.2 deletion syndrome using limited deoxynucleotide triphosphates and high-resolution melting. |
Q89641284 | Analysis of FUS, PFN2, TDP-43, and PLS3 as potential disease severity modifiers in spinal muscular atrophy |
Q93088149 | Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy |
Q100504061 | CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening |
Q91784761 | Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype |
Q52804349 | Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany. |
Q92297063 | High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR |
Q90124758 | Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden? |
Q99585557 | Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy |
Q104567667 | Molecular diagnosis and genetic counseling for spinal muscular atrophy (SMA) |
Q98945157 | NGS-based spinal muscular atrophy carrier screening of 10,585 diverse couples in China: a pan-ethnic study |
Q64276902 | Neurofilament as a potential biomarker for spinal muscular atrophy |
Q58779205 | New Directions for SMA Therapy |
Q92539534 | Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry |
Q89595212 | Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients |
Q64075875 | Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy |
Q90593635 | One Year of Newborn Screening for SMA - Results of a German Pilot Project |
Q104567661 | Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA) |
Q91752254 | Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors |
Q89626564 | RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design |
Q100566572 | SMN1 copy-number and sequence variant analysis from next-generation sequencing data |
Q100559905 | Spinal muscular atrophy - insights and challenges in the treatment era |
Q92146942 | The frequency of SMN gene variants lacking exon 7 and 8 is highly population dependent |
Q90679196 | The implementation of newborn screening for spinal muscular atrophy: the Australian experience |
Q89109004 | Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling |
Search more.